News from eidos therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 19, 2018, 10:49 ET Eidos Therapeutics Announces Pricing of Initial Public Offering

Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...

May 03, 2018, 08:00 ET Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), ...

Apr 05, 2018, 08:00 ET Eidos Therapeutics completes $64M Series B financing

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), ...

Jan 05, 2018, 08:00 ET Eidos Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

Eidos Therapeutics, a clinical stage biopharmaceutical company, today announced that Neil Kumar, Ph.D., the company's chief executive officer, will...

Nov 15, 2017, 07:00 ET Preclinical Data Demonstrates Potential of Eidos Therapeutics' Lead Compound for the Treatment for Transythyretin Amyloidosis

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced that recently presented preclinical data highlight the potential of AG10 to...

Nov 09, 2017, 07:00 ET Eidos Therapeutics to Present Data on its Potential Treatment for Transthyretin Amyloidosis at the American Heart Association

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced two upcoming oral presentations regarding AG10, its therapeutic candidate for...

Sep 28, 2017, 08:00 ET Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced dosing of the first healthy adult cohort in the first-in-human, Phase 1...

Apr 27, 2017, 08:00 ET BridgeBio Pharma Launches Eidos Therapeutics to Develop Targeted Therapy for Fatal Heart Disease

BridgeBio Pharma today announced the launch of Eidos Therapeutics, a biopharmaceutical company developing a novel small-molecule treatment for...